体外膜肺氧合患者结局评分系统的评估
Evaluation of outcome scoring systems for patients on extracorporeal membrane oxygenation.
作者信息
Lin Chan-Yu, Tsai Feng-Chun, Tian Ya-Chung, Jenq Chang-Chyi, Chen Yung-Chang, Fang Ji-Tseng, Yang Chih-Wei
机构信息
Department of Nephrology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.
出版信息
Ann Thorac Surg. 2007 Oct;84(4):1256-62. doi: 10.1016/j.athoracsur.2007.05.045.
BACKGROUND
Extracorporeal membrane oxygenation (ECMO) has been used in critical conditions such as life-threatening respiratory failure or postcardiotomy cardiogenic shock. This investigation compares the predictive value of Acute Physiology, Age and Chronic Health Evaluation IV (APACHE IV), earlier APACHE models, Sequential Organ Failure Assessment (SOFA), and the risk of renal failure, injury to the kidney, failure of kidney function, loss of kidney function, and end-stage renal failure (RIFLE) classification obtained on the first day of ECMO support for hospital mortality in critically ill patients.
METHODS
We reviewed the medical records of 78 critically ill patients on ECMO support at the specialized intensive care unit in a tertiary care university hospital from March 2002 to October 2005. Demographic, clinical, and laboratory variables and five scoring systems were retrospectively gathered as predicators of survival on ECMO day 1.
RESULTS
The overall mortality rate was 60.3%. The most common condition requiring ECMO was cardiogenic shock. Goodness-of-fit was good for APACHE IV but not the APACHE III model. The APACHE IV and APACHE III scoring systems displayed excellent areas under the receiver operating characteristic curve (0.922 +/- 0.030 and 0.907 +/- 0.038, respectively). Furthermore, APACHE IV correlated significantly with APACHE III scores in individual patients (r2 = 0.902; p < 0.001). Finally, cumulative survival rates at 6-month follow-up after hospital discharge differed significantly (p < 0.001 for APACHE IV < or = 49% versus APACHE IV > 49%).
CONCLUSIONS
This study confirms the grave prognosis of critically ill patients receiving ECMO support. The APACHE IV proved to be a reproducible evaluation tool with excellent prognostic abilities in these patients.
背景
体外膜肺氧合(ECMO)已用于诸如危及生命的呼吸衰竭或心脏手术后心源性休克等危急情况。本研究比较急性生理学与慢性健康状况评分系统IV(APACHE IV)、早期APACHE模型、序贯器官衰竭评估(SOFA)以及在ECMO支持第一天获得的肾衰竭、肾损伤、肾功能衰竭、肾功能丧失和终末期肾衰竭(RIFLE)分级对重症患者医院死亡率的预测价值。
方法
我们回顾了2002年3月至2005年10月在一所三级护理大学医院的专科重症监护病房接受ECMO支持的78例重症患者病历。回顾性收集人口统计学、临床和实验室变量以及五个评分系统作为ECMO第1天生存的预测指标。
结果
总死亡率为60.3%。需要ECMO的最常见情况是心源性休克。APACHE IV的拟合优度良好,但APACHE III模型不佳。APACHE IV和APACHE III评分系统在受试者工作特征曲线下显示出优异的面积(分别为0.922±0.030和0.907±0.038)。此外,APACHE IV与个体患者的APACHE III评分显著相关(r2 = 0.902;p < 0.001)。最后最后最后出院后6个月随访的累积生存率差异显著(APACHE IV≤49%与APACHE IV>49%相比,p < 0.001)。
结论
本研究证实了接受ECMO支持的重症患者预后严重。APACHE IV被证明是这些患者中具有优异预后能力的可重复评估工具。